Docking of Ambrisentan and Teneligliptin with IL‐36G confirmed their binding energies were also less than −5.0 kcal/mol (Figure 6D,E), demonstrating that these small‐molecule drugs can bind to IL‐36G and exert potential therapeutic effects, making them promising candidates for treating atopic dermatitis and psoriasis. Here, IL36G is linked to psoriasis.